期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肥胖和代谢综合征的药物治疗与研究进展 被引量：5

Research progress of the drug treatment of obesity and metabolic syndrome
下载PDF
导出
摘要 肥胖与IR被公认为是代谢综合征的重要致病因素,本文通过讨论肥胖和脂肪组织的关系综述了目前食欲抑制剂、消化吸收阻滞剂、降糖药物(双胍类、α-糖苷酶抑制剂、GLP-1和DPP-4抑制剂)和代谢刺激剂在肥胖药物治疗中的研究进展;同时又从脂代谢异常角度讨论了胰岛素增敏剂和调脂药物(他汀类、贝特类和烟酸)在代谢综合征的药物治疗中研究进展。最后结论为调脂药物的研究已获得广泛成效,但新的减肥药物的研发仍有待进一步突破。
作者 黄建权 王观春 由凯
机构地区 航天中心医院药剂科
出处 《药品评价》 CAS 2013年第9期25-32,共8页 Drug Evaluation
关键词 肥胖 代谢综合征 西布曲明 奥利司他 噻唑烷二酮 调脂药物
分类号 R589.2 [医药卫生—内分泌]
  • 相关文献

参考文献64

  • 1Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease[J]. Diabetes, 1988, 37(12): 1595-1607.
  • 2Reaven GM. Pathophyiology of insulin resistance in human disease[J]. Physiol Rev, 1995, 75 (3): 473-486.
  • 3Stern ME Diabetes and cardiovascular disease. The "common soil" hypothesis[J]. Diabetes, 1995, 44 (4): 395-374.
  • 4World Health Oganization. Definition, diagnosis and classification of diabetes mellitus and its complications[M].Geneva: World Health Organization, 1999.
  • 5National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report[J]. Circulation, 2002, 106(25): 3143- 3421.
  • 6Cheal KL, Abbasi F, Lamendola C, et al. Relationship to insulin resistance of the adult treatment panel In diagnostic criteria for identification of the metabolic syndrome[J]. Diabetes, 2004, 53(5): 1195- 1200.
  • 7宋秀霞 ,纪立农 .国际糖尿病联盟代谢综合征全球共识定义[J].中华糖尿病杂志（1006-6187）,2005,13(3):178-180. 被引量：610
  • 8Cart DB, Utzsehneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel Ⅲ criteria for the metabolic syndrome[J]. Diabetes, 2004, 53(8): 2087-2094.
  • 9Ponliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometrie indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women[J]. Am J Cardinl, 1994, 73(7): 460-468.
  • 10Kissebah AH, Krakower GR. Regional adiposity and morbidity[J]. Physiol Rev, 1994, 74(4): 761-811.

二级参考文献155

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华糖尿病杂志,2010,2(1). 被引量：525
  • 2黄建权,傅得兴,胡欣,张君仁.抗糖尿病药物维达列汀[J].中国新药杂志,2007,16(6):486-488. 被引量：11
  • 3International diabetes federation. Did you know[ EB/OL]. [2006- 09-23]. http://www, idf. org/home/index, cfm? unode =3B96906B - C026 - 2FD3 - 87B73 F80BC22682A.
  • 4KIM D, WANG L, BECONI M, et al. (2R)4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro [ 1,2, 4 ] triazolo [ 4, 3-a ] pyrazin-7 (8H) -yl ] -1 -( 2,4,5-trifluorophenyl ) butan-2-amine : A potent, orally active dipeptidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes[J]. J Med Chem, 2005,48( 1 ) :141-151.
  • 5NAUCK M A, MEIER J J. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes [ J ]. Regul Pept, 2005, 124(Suppl) :135-148.
  • 6DRUCKER D J. Enhancing incretin action for the treatment of type 2 diabetes [ J ]. Diabetes Care, 2003,26 ( 10 ) :2929-2940.
  • 7NAUCK M A, NIEDEREICHHOLZ U, ETrLER R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans [ J ]. Am J Physiol (Endocrinol Metab), 1997,273 (5) :981-988.
  • 8PERFETTI R, HUI H. The role of GLP-1 in the life and death of pancreatic beta cells [ J ]. Horm Metab Res, 2004,36 ( 11-12 ) : 804-810.
  • 9TRUMPER A, TRUMPER K, TRUSHEIM H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling [ J ]. Mol Endocrinol, 2001,15(9) :1559-1570.
  • 10MENTLEIN R. Dipeptidyl-peptidase Ⅳ (CD26) -role in the inactivation of regulatory peptides [ J ]. Regul Pept, 1999,85 ( 1 ):9- 24.

共引文献684

同被引文献64

  • 1任贵英.绞股蓝总甙治疗高脂血症80例疗效观察[J].四川医学,2006,27(6):606-607. 被引量：15
  • 2邓胜国,邓泽元,黄丽.荷叶黄酮体外抗氧化活性的研究[J].食品科技,2006,31(7):274-276. 被引量：50
  • 3谭华炳.绞股蓝对兔高脂血症与血液流变学影响的研究[J].第三军医大学学报,2007,29(15):1497-1499. 被引量：34
  • 4He Min,Su Haoran,Gao Weiwei,et at. Reversal of obe- sity and insulin resistance by a non-peptidic glucagon- like peptide-1 receptor agonist in diet-induced obese mice[J]. PloS one,2010,5(12) : 1-15.
  • 5Shih Chun-Ching, Lin Cheng-Hsiu, Lin Wei-Li. Effects of Momordica charantia on insulin resistance and viscer- al obesity in mice on high-fat diet[J]. Diabetes Research and Clinical Practice, 2008,81 ( 2 ) : 134-143.
  • 6Lee YS,Cha BY, Saito K,et al. Effects of a Citrus de- pressa Hayata (shiikuwasa) extract on obesity in high- fat diet-induced obese mice[J]. Phytomedicine, 2011,18 (8-9) :648-654.
  • 7Huang T H, Tran V H, Roufogalis B D, et al. Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits expression and activity in LPS-induced human THP-1 tissue factor monocytic cells [ J]. Toxicol Appl Pharmacol,2007,218( 1 ) :30-36.
  • 8潘建国,王开发,段怡.试论花粉调节血脂的机制与新进展[J].蜂产品专刊,2002,18(6):23-26.
  • 9Bohler H Jr, Mokshagundam S, Winters SJ. Adipose tissue and re- production in women [J]. Fertil Steril, 2010, 94(3): 795-825.
  • 10Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uter- ine leiomyom as: A review [J]. Environ Health Perspect, 2003, ll l: 1037-1054.

引证文献5

二级引证文献30

药品评价
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部